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     Abstract: 
In this paper, an electrospray technique followed by annealing at high temperatures was 
developed to produce nanocrystals of carbamazepine (CBZ), a poorly water-soluble drug, for 
continuous pharmaceutical manufacturing process. Electrospraying solutions of CBZ in 
methanol obeys the expected scaling law of current, which is I~ Q1/2, for liquids with sufficiently 
high conductivity and viscosity. Lower flow rates during electrospraying were preferred to 
produce smaller diameters of monodisperse, dense CBZ nanoparticles. CBZ nanoparticles were 
predominantly amorphous immediately after electrospraying. Crystallization of CBZ 
nanoparticles was accelerated by annealing at high temperatures. CBZ nanocrystals with the 
most stable polymorph, form III, were obtained by annealing at 90⁰C, which is above the 
transition temperature, 78⁰C, for the enantiotropic CBZ form III and form I. The solubility and 
dissolution rates of CBZ nanocrystals increased significantly compared to those of CBZ bulk 
particles. Therefore, electrospray technology has the potential to produce pharmaceutical dosage 
forms with enhanced bioavailability and can readily be integrated in a continuous pharmaceutical 
manufacturing process. 
 
Keywords: electrospray, nanocrystal, crystallization, polymorphism, continuous pharmaceutical 
manufacturing. 
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Introduction 
Currently, pharmaceutical solid dosage forms are manufactured mainly using batch processes. 
However, there are tremendous potential benefits in transforming the current pharmaceutical 
manufacturing process into a continuous process, which will increase the efficiency and quality, 
and reduce the cost, of the final products1-2.  Electrostatic atomization or “electrospraying” is one 
of the most effective techniques to produce monodisperse particles with diameters ranging from 
several micrometers down to tens of nanometers3-4. As a pharmaceutical process step, 
electrospraying utilizes electrical forces to convert solution of active pharmaceutical ingredients 
(APIs) and excipients directly into solid particles in a single step at room temperature. 
Electrospray technology can be easily operated in a continuous manner. Therefore, electrospray 
technology has the potential to replace multiple unit operations in pharmaceutical manufacturing 
such as drying, filtration, blending and granulation, and can be integrated into a continuous 
pharmaceutical manufacturing process for solid dosage forms. However, the effect of 
electrospraying process on the morphology, crystallinity and polymorphism of APIs during and 
after the electrospray has not been well understood.   
 
Electrospraying can be operated in one of several modes5.In the cone-jet mode, it can be 
described simply in three stages: first, the acceleration of the liquid in the liquid cone and 
ejection of a charged, liquid jet from the cone apex due to the competition of stresses due to 
surface tension, electrical stresses in the liquid surface, inertia and viscosity; second, the breakup 
of the jet into droplets; third, evolution of the droplet population after its initial formation5-6. 
During the third stage, the evaporation of charged droplets is governed by the basic laws of heat 
and mass transfer 7-8. Furthermore, Coulomb fission of charged droplets can occur when the 
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charge density on the droplet surface reaches the Rayleigh limit due to droplet shrinkage 
associated with solvent evaporation 9. At the Rayleigh limit, electrostatic charge repulsion 
overcomes surface tension, and a charged droplet emits a cloud of small but highly charged 
offspring droplets. 
 
Approximately 40% or more of the new drugs synthesized by the pharmaceutical industry are 
poorly soluble in water 10. Due to the low solubility, these poorly water-soluble drugs possess 
very low dissolution rates and poor bioavailability. It is very difficult to overcome this problem 
using conventional formulation approaches, so many drugs have to be abandoned early in the 
discovery process. Recently, formulation as nanocrystals with typical sizes ranging from 10-
1000 nm has been considered as a viable drug delivery strategy to improve the bioavailability, 
dosage proportionality and patient safety of poorly water-soluble drugs 11-14. Due to the smaller 
size and higher surface to volume ratio, nanocrystal formulation increases significantly the 
solubility and the dissolution rates of poorly water-soluble drugs 15-16. 
 
Most APIs are polymorphic, exhibiting more than one form of crystal structure 17-22. Different 
polymorphs of an API tend to differ in such characteristics as crystal habit, solubility and 
hardness, which in turn can have a large impact on the physical and chemical stability, 
manufacturability and bioavailability of the final dosage form. Generally, the most stable 
polymorphs are desired to ensure the physical and chemical stability of APIs in the final dosage 
forms 23-24.   
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CBZ is a class II, anti-epileptic drug and has high intestinal permeability. But the bioavailability 
of CBZ is limited due to its low solubility in water.CBZ exists in at least four anhydrous forms: 
primitive monoclinic (III), C-centered monoclinic (IV), trigonal (II), and triclinic (I). Among 
these, the form III is the most stable polymorph under ambient conditions25-26. 
 
Herein we describe an electrospray technique followed by annealing at high temperature to 
produce nanocrystals of CBZ with the most stable form III for continuous pharmaceutical 
manufacturing.  The effects of the solution properties and operating parameters on the 
morphology, crystallinity and polymorphism of CBZ nanocrystals are described. The solubility 
and dissolution rates of the nanocrystals are also reported. 
 
Materials and Methods: 
Methanol and carbamazepine (CBZ) were purchased from Sigma Aldrich. Due to its relatively 
high dielectric constant and suitable boiling point, methanol was chosen in this study as the 
solvent for electrospraying CBZ solutions. Solutions of CBZ in methanol at various 
concentrations were prepared by dissolution with vigorous stirring at room temperature. CBZ 
material as received was pure CBZ form III. CBZ form I was obtained by heating the as-received 
CBZ material at 170⁰C for 4 hours 25-26. 
A parallel-disk electrospray apparatus was used in this study, as described by Fridrikh et al27.  
The inner and outer diameters of the steel needle (Upchurch Scientific, WA) were 0.25 and 1.58 
mm, respectively. An adjustable insulated stand was used to support the collector disk, which 
was covered by a layer of aluminum foil ( Reynolds, VA ). A digital multi-meter (Fluke 85 III) 
was used to measure the voltage drop across a 1.0 MΩ resistor connected between the collector 
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disk and the ground, which was then converted to electric current using Ohm’s law. A distance 
of 20 cm between the high voltage disk electrode and the collector disk was used to allow the 
complete evaporation of solvent, which was subsequently confirmed by gas chromatographic 
analysis of the CBZ nanoparticles after electrospraying. The electric field and solution flow rate 
were adjusted to obtain a stable cone-jet for the electrospray, which was monitored by a 
microscopic lens (AF-S Micro, Nikon) and a digital camera. CBZ nanoparticles were carefully 
harvested from the aluminum foil on the collector disk by a razor blade (VWR Scientific., PA). 
CBZ nanoparticles were also directly electrosprayed into a grounded, circular liquid nitrogen 
bath with a diameter of 30cm, housed in a plexiglass chamber in which the relative humidity 
(RH) was maintained below 8% at room temperature. The CBZ nanoparticles were then 
harvested from the liquid nitrogen bath immediately after the evaporation of the liquid nitrogen. 
After harvesting, the CBZ nanoparticles were annealed in an oven (Model 281A, Cole Parmer, 
IL) at either 60 ⁰C or 90 ⁰C for various lengths of time. CBZ nanoparticles on the aluminum foil 
were also annealed in the oven at 90 ⁰C and were used for SEM imaging, solubility and 
dissolution measurements. 
 
Micrographs of CBZ nanoparticles were taken using a JEOL-6060 scanning electron microscope 
(SEM) (JEOL Ltd, Japan).  Particle size distribution was determined by analysis of SEM images 
using the Infinity Analyzer V.5 software (Lumenera corp., Ottawa, Canada). X-ray diffraction 
(XRD) data were obtained using a PANalytical X’Pert(Bruker, Madison,WI) with CuKα 
radiation at 45 kV and 40 mA. The reflected intensity was collected at 2θ angles from 5⁰ to 40⁰ 
with a step size of 0.02⁰. The ratio of areas of the peaks at 2θ=12.5⁰ and 13.3⁰for mixtures of 
pure form I and form III with known compositions was used to construct a linear calibration 
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curve for polymorphic compositions. The lower detection limit for CBZ form I in the mixture by 
the XRD is 10 wt%. Thermograms of CBZ nanoparticles were obtained using differential 
scanning calorimetry (DSC) Q2000 (TA Instruments, DE). The samples were scanned at a speed 
of 5 ⁰C/min from 25 ⁰C to 220⁰ C under nitrogen atmosphere at a flow rate of 150 mL/min. The 
percent crystallinity was determined by dividing the absolute difference of the heats of melting 
and cold crystallization of nanoparticles by the heat of melting of 100% CBZ crystals 28. 
 
A saturated solution of CBZ was prepared by adding an excess of CBZ particles as received into 
20 ml water. The solution was vigorously stirred for at least 2 hours at 25 ⁰C, and then filtered 
using a 0.2 µm PTFE syringe filter (Pall Corp. NY). The solubility of CBZ nanocrystals was 
measured by immersing CBZ nanocrystals complete with the aluminum foil (1x3cm) into the 
saturated bulk CBZ solution prepared as described above. The solutions were vigorously stirred 
for 20 mins.  Any undissolved CBZ nanoparticles on the aluminum foil were generally 
noticeable by eye. The solutions were filtered by a 0.2 µm PTFE syringe filter and assayed by a 
HP 89090A UV-Vis spectrometer (Hewlett Packard, CA) at 285 nm. Three replicates of each 
solubility test were performed. 
 
Tests for dissolution of CBZ nanocrystals were carried out using an Agilent 708-DS dissolution 
apparatus (Agilent Technologies, CA) following USP apparatus 1(basket) method. The medium 
was 900 ml of 0.01N HCl solution. The solutions were stirred at 50 rpm and 37±0.5⁰C. The 
dissolution of CBZ was measured by the UV absorbance at 285nm every two minutes for 2 
hours. The samples were prepared by cutting the aluminum foil covered with CBZ nanocrystals 
into 1x2cm sections.  The exact weights of CBZ samples were calculated by measuring the 
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weights of aluminum foil before and after the tests. The dissolution of large CBZ particles as 
received was also measured for comparison. Three replicates of each dissolution rate test were 
performed. 
 
Results and Discussions: 
Scaling law: 
Table 1 lists the typical processing parameters used for electrospraying various solutions of CBZ 
in methanol. The optimum range of CBZ concentration, Cw, in methanol solvent for continuous, 
steady electrospraying was found to be 0.5 to 5 wt%. Higher CBZ concentrations (>5 wt%) 
could easily lead to the precipitation of CBZ at the Taylor-cone stage and render the electrospray 
unstable.  
 
To characterize the electrospraying process, the operating parameters of flow rate and electrical 
current, and the diameter of droplets produced, were nondimensionalized using the scaling 
factors proposed by Gañán-Calvo: 29 
 
       
where Q0, d0 and I0 are scaling parameters for flow rate, jet diameter and electrical current, 
respectively. γ is the gas-liquid surface tension, ρ and K are the density and electrical 
conductivity of the solution, respectively; ε0 is the permittivity of vacuum. δ andδu are defined as 
the inverse of the dimensionless flow rate and  dimensionless viscous parameter, respectively:  
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where Q is the flow rate and  µ is the viscosity of the solution.  
 
For electrospraying CBZ solutions at various conditions during this study, δuδ1/3<1. As shown by 
Gañán-Calvo, this is the condition for which the radial profile of axial velocity of the CBZ liquid 
jet is flat, and for which the electrospray current and droplet diameter obey the scaling laws I~ 
Q1/2 and d~Q1/3, respectively 29-31. Those behaviors are typically observed for liquids of 
sufficiently high viscosity and conductivity in electrospraying. 
 
Figure 1 shows a plot of I/I0 versus (Q/Q0)1/2 for all concentrations of CBZ solutions within the 
range of flow rates required for electrospraying in the cone-jet mode. As expected, a linear 
relationship is observed between the I/I0 and(Q/Q0)1/2  with  R2=0.96.  The recently reported 
scaling of current in electrospinning jets32, obtained using the same type of apparatus, is I ~ 
EQ1/2. 
 
 
Morphology of CBZ nanoparticles: 
Assuming that atomization occurs through an axisymmetric varicose instability and that the 
radial profile of axial velocity of the jet is flat, the droplet diameter, dd, can be calculated using 
eq. (3), 5-6: 
 
 
fb is the nondimensional radius of the jet at the breakup point. Its average value is estimated to be 
0.6 within error of the order of 25% 31. Figure 2 compares the measured diameters of CBZ 
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nanoparticles for 0.5-3wt% CBZ concentrations and the calculated diameters of the 
nanoparticles, dp, from the diameter of droplets using equation 3 and 4, assuming the CBZ 
nanoparticles are spherical and nonporous 33. 
 
 
Where ρs and ρp are the densities of the solvent and the solid material, respectively. As shown in 
Figure 2, the diameters of the CBZ particles increased with flow rate for all CBZ concentrations. 
At low flow rates (Q=0.003 or 0.005 ml/min), the experimentally observed diameters were 
similar to the calculated CBZ diameters. But at high flow rates (Q=0.01 or 0.02 ml/min), the 
experimentally observed diameters were larger than the calculated diameters. This is attributed to 
the formation of a skin layer, as described below. 
 
During electrospraying, the morphology of the solute particle is largely determined by the 
competition among the processes of solvent evaporation, diffusion of solute molecules toward 
the droplet core and Coulomb fission34-35.  The solute particles are the relics obtained after 
solvent evaporation from the precursor spray droplets. The competition between solvent 
evaporation and solute diffuion can be described by a modified Peclet number, Pe, 36-38.:  
 
 
 
Where D is the diffusion coefficient of methanol vapor in air, which is calculated to be 0.11 
cm2/s using the critical temperatures and pressures of air and methanol 39. ρAir ,and ρMe are the 
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vapor at the droplet surface and far away from the droplet, respectively. The ambient phase is 
assumed to be a sink for methanol vapor, so 0, =!Mex . DCBZ,Meis the mutual diffusion coefficient 
of CBZ in liquid methanol. 
 
From the Wilke-Chang equation39: 
 
 
where VCBZ is the molar volume of the CBZ, µme is the viscosity of the methanol at T0, φme is an 
“association parameter” for the solvent, whose value is 1.9 for the methanol, and T0 is the 
absolute temperature of the droplet, which is 265K for a methanol droplet evaporating in a 
vapor-free gas at 293K 40. 
 
For all concentrations of the CBZ solutions, Pe>1. This indicates that solvent evaporates away 
from the droplet surface faster than CBZ can diffuse towards the core, resulting in increased 
concentration of CBZ at the droplet surface. If the concentration of CBZ at the droplet surface 
exceeds the saturation concentration (~9.8 wt%),  CBZ precipitates out and forms a skin layer. 
The larger the diameter of the droplet, the more likely it is that a skin layer forms.The skin layer 
may then remain intact or collapse, depending on the porosity, thickness and modulus of the 
solid skin 41-44. The diameters of nanoparticles were mostly determined by the diameter of the 
solid skin formed.  
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Figure 3 shows some representative SEM images of CBZ nanoparticles produced by 
electrospraying at various concentrations and flow rates. For 0.5 wt% CBZ solution, at low flow 
rates, solid, dense particles of small diameter were observed, as shown in Figure 3a,b. At high 
flow rates, collapsed CBZ particles were observed, as shown by the representative image in 
Figure 3c, indicating the formation and collapse of a CBZ skin layer. Similar results were 
observed for 1 wt% and 3 wt% CBZ solutions, as shown by representative images in Figures 3d, 
e. These results are consistent with the results from the above comparison of measured diameters 
with calculated diameters of CBZ nanoparticles. However, CBZ particles electrosprayed from 5 
wt % CBZ solution at high flow rates (Q=0.01 or 0.02 ml/min), as shown in the representative 
Figure 3f, have a smooth solid surface. This is probably because the higher concentration of CBZ 
solution led to the formation of a thicker skin layer that can resist the buckling collapse under 
atmospheric pressure 41-42. Therefore, to produce smaller diameters of solid, dense nanoparticles, 
it is desirable to lower the flow rates, to reduce or avoid the formation of the skin layer. 
 
  
Another process that can affect the morphology of CBZ nanoparticles during electrospraying is 
Coulomb fission of the charged droplets when the surface charge density at the droplet surface 
exceeds the Rayleigh limit. When Coulomb fission occurs, the charged droplets emit a cloud of 
very small droplets, leaving behind relatively large parent particles as well. As a result, a 
bimodal distribution of CBZ nanoparticles is obtained.  Assuming the evaporation process occurs 
without loss of CBZ solute, the CBZ volume fraction, φRay, in the droplet at the moment it 
reaches the Rayleigh limit can be calculated as 34:  
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whereφ0 is the initial volume concentration of CBZ in solution. 
We can compare φRay with the saturation concentration of CBZ in methanol, which is 5.9% by 
volume. If φRay is less than 5.9vol%, Coulomb fission can occur. Otherwise, CBZ precipitates out 
from solution before the Rayleigh limit is reached, and Coulomb fission is avoided. Figure 4 
shows φRayvs flow rate for various concentrations of CBZ solutions. As shown in Figure 4, as the 
flow rate increases, φRay decreases for all concentrations of CBZ solutions. This indicates that at 
lower flow rates, it is less likely that Coulomb fission occurs. For 0.5 wt% solution, at Q= 0.003 
ml/min, φRayis greater than 5.9 vol%, indicating no Coulomb fission. At Q=0.005 ml/min,φRayis 
close to 5.9 vol%, indicating a borderline case for Coulomb fission. At Q= 0.01 and 0.02 ml/min, 
φRayis less than 5.9%, indicating that Coulomb fission is likely. These phenomena were 
confirmed visually from the SEM images as shown in Figure 3a,b and c, respectively. Similar 
results were observed for 1 wt% CBZ solutions. However, for 3 wt% and 5wt%, the φRaywas 
greater than 5.9 % at all flow rates, indicating low probability of Coulomb fission at all flow 
rates.  These phenomena were also visually confirmed from the SEM images, as shown by the 
representative images in Figures 3e and 3f.  
 
In summary, from the foregoing analysis, in order to produce monodisperse, dense nanoparticles 
with small diameters, it is desirable to electrospray at low flow rates to reduce or avoid the 
possibility of solid skin formation as well as Coulomb fission. 
 
14 
 
 
Crystallinity and polymorphism of CBZ nanoparticles: 
In order to examine the effect of the electrospray process on the crystallinity of CBZ 
nanoparticles, a 1 wt% CBZ solution was electrosprayed directly into a liquid nitrogen bath at 
low humidity (RH<8%) in order to quench the particles immediately upon deposition and avoid 
subsequent crystallization on the collector. For comparison, solids of pure CBZ forms I or III 
were also immersed into liquid nitrogen bath and harvested in the same way as the CBZ 
nanoparticles. The XRD spectra of CBZ nanoparticles collected by the liquid nitrogen bath, and 
of pure CBZ form I and form III treated by the liquid nitrogen bath, are compared in Figure 5. 
The CBZ nanoparticles, electrosprayed from different solution concentrations and flow rates,  
show the XRD pattern of CBZ dihydrate while the XRD spectra for pure CBZ form I and III 
were unchanged by the liquid nitrogen treatment. The absence of a peak at 2θ=13.3⁰  in the 
spectra for CBZ nanoparticles indicates that there was no form I or III in the CBZ nanoparticles. 
Subsequent analysis of CBZ nanoparticles after 8 hours of continuous electrospraying under 
ambient conditions excluded the possibility of CBZ form II and IV in the CBZ nanoparticles. 
Therefore it can be reasonably concluded that the CBZ nanoparticles were amorphous 
immediately upon deposition by electrospraying, and that the amorphous CBZ nanoparticles 
quickly absorbed water condensed from the air due to evaporative cooling and transformed into a 
CBZ dihydrate. During electrospraying, the CBZ solution was electrified into a mist of tiny 
droplets with diameters in the range of 1-5 µm. The time for drying these methanol droplets is 
estimated to be 0.2-2 ms45. In addition, due to the evaporative cooling, the temperature on the 
surface of the methanol droplets decreases to around 265K 45-46. Interaction of the electrical field 
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(E=7.6x104V/m) with the dipole moment of the CBZ molecule (σ=12x10-30 C m)47 was also 
calculated.  The value obtained of Eσ=9.1x10-25 J is much smaller than the thermal energy kT = 
3.65x10-21 J, where k is the Boltzmann constant. This effectively excludes the possible influence 
of the electrical field on the crystallization of CBZ nanoparticles during  electrospraying. 
Therefore, the fast evaporation rate and low temperature on the droplet surface dominates the 
electrospray process and creates a high CBZ supersaturation in a very short time inside the 
droplets, which leads to the amorphous CBZ nanoparticles 48-50. 
 
At room temperature, amorphous API nanoparticles can continue to crystallize with time during 
and after electrospraying. The rate of crystallization depends on the nucleation and growth rate 
of the specific API at room temperature.  The XRD spectra of CBZ nanoparticles harvested on 
the collector disk after 8 hours of continuous electrospraying of 1 wt% CBZ solution at various 
storage times under  ambient conditions and those of the pure CBZ polymorphs  are compared in 
Figure 6. As highlighted by the dashed lines, the peak at 2θ= 12.5⁰ is present only in form I (in 
Figure 6d), not in form III (Figure 6e), while the peak at 13.3⁰is present in both forms. By 
measuring the XRD spectra of mixtures of pure forms I and III at various composition ratios, a 
linear relationship was obtained between the ratio of the two peak areas at 2θ= 12.5⁰ and 13.3⁰ 
and the percentage of form I in the mixtures. Therefore, the ratio of two peak areas at 2θ = 12.5⁰ 
and 13.3⁰ was used to calculate the ratio of the CBZ form I and form III in the nanoparticles. As 
shown in Figure 6(a), the spectrum for CBZ nanoparticles collected after 8 hours of continuous 
electrospraying shows many small diffraction peaks overlapping a large amorphous halo 
underneath. This indicates that a fraction of the CBZ nanoparticles on the collector disk 
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crystallized during the 8 hours of continuous electrospraying. The peak positions matched well 
with the peak positions of pure form III (Figure 6(e)), indicating that the CBZ nanoparticles were 
partially crystallized in form III. After an additional 12 hours of storage, a small characteristic 
peak of CBZ form I at 2θ= 12.5⁰appeared, indicating the concomitant polymorphism of CBZ 
crystallization during the storage (Figure 6b).At t=18 days, the CBZ form I peak at 2θ= 12.5⁰ 
had increased (Figure 7c), and the ratio of CBZ form III to form I in the CBZ nanoparticles was 
4:1.  The evolution of XRD spectra for CBZ nanoparticles produced at different operating 
conditions with time showed similar patterns. It is worthwhile to point out here that the extent 
of crystallization and polymorphic composition of the CBZ nanoparticles were still evolving 
after 3 weeks of storage time. Therefore it is highly desirable to develop a method to accelerate 
the crystallization and stabilize the polymorphs of CBZ nanoparticles in a practical time frame 
for continuous pharmaceutical manufacturing. 
 
To accelerate the crystallization of CBZ nanoparticles, the CBZ nanoparticles were annealed at 
different temperatures for various periods of time. The XRD spectra of annealed CBZ 
nanoparticles are shown in Figure 7. After annealing at 60 ⁰C for 5 mins, CBZ nanoparticles 
showed the XRD pattern of a mixture of forms I and III(Figure 7a). Using the ratio of two peak 
areas at 2θ= 12.5⁰ and 13.3⁰, the calculated ratio of CBZ form III to form I was 2 to 3. 
However, when CBZ nanoparticles were annealed at 90 ⁰C for 5 mins, the peak at 2θ= 
12.5⁰disappeared, indicating that CBZ crystallized predominately in form III (Figure 7b). 
Extending the time of annealing to 40 min did not change the XRD spectrum significantly (Figure 
7c).  The difference in crystal forms exhibited by CBZ nanoparticles annealed at different 
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temperatures can be explained by the enantiotropic nature of CBZ form III and form I. The 
transition temperature for enantiotropic CBZ form III and form I is approximately 78 ⁰C [51]. 
Below 78 ⁰C, form I is meta-stable with respect to form III . However, above the 78 ⁰C, form III 
is meta-stable with respect to  form I  52-53. Therefore annealing CBZ nanoparticles at 60 ⁰C 
accelerates the crystallization and converts the amorphous part to meta-stable form I in the CBZ 
nanoparticles according to the Ostwald’s rule of stages.  Combining with the original form III 
formed during electrospraying, these CBZ nanoparticles show a mixture of form III and I. 
However, annealing CBZ nanoparticles at 90 ⁰C also produced the meta-stable polymorph, 
which is form III at high temperatures. As a result, CBZ form III is predominately produced in 
these nanoparticles. As the CBZ nanoparticles annealed at 90 °C cooled to  room temperature, 
the CBZ form III is retained and becomes the most stable polymorph. SEM images (not shown) 
confirmed that the size of the nanoparticles was maintained after annealing at 90 ⁰C for 5 mins. 
Therefore, CBZ nanocrystals with the most stable form III were produced by an electrospray 
technique followed by annealing at 90 ⁰C. 
 
 
The DSC thermograms of CBZ nanoparticles harvested after 8 hours of continuous electrospray, 
before and after annealing, and those of the pure CBZ forms are compared in Figure 8. For pure 
CBZ form III (Figure 8c), two endothermic peaks are observed. The peak at 165⁰C is due to the 
solid-solid transformation from form III to form I, and the peak at 191⁰C is due to the melting of 
form I 54-55.  For pure CBZ form I (Figure 8d), only one melting peak, at 191⁰C, is observed.  For 
CBZ nanoparticles collected immediately after 8 hours of continuous electrospray, before the 
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annealing, three peaks are observed (Figure 8a). A broad exothermic peak from 50 ⁰C to 75 ⁰C, 
marked by an arrow, is due to the cold crystallization of CBZ nanoparticles, which indicates that 
the CBZ nanoparticles were initially at least partially amorphous. The second endothermic peak 
at 157 ⁰C, marked by an arrow, is the transition peak from CBZ form III to Form I, and the third 
endothermic peak at 191 ⁰C is the melting peak of CBZ form I.  The percent crystallinity of 
CBZ nanoparticles immediately after 8 hours of continuous electrospraying was calculated to be 
approximately 60±10%. After annealing at 90 ⁰C for 5 mins, the DSC thermogram of CBZ 
nanoparticles shows two endothermic peaks. The disappearance of the exothermic peak from 50 
⁰C to 75 ⁰C indicates that CBZ nanoparticles were predominantly crystallized by the annealing 
process such that no significant amount of cold crystallization takes place. The endothermic 
peaks at 157 ⁰C and 191⁰C are the transition peaks from CBZ form III to I and melting peak of 
CBZ form I, respectively.  All of these results are consistent with the XRD results. 
       
 
Solubility and dissolution profiles of CBZ nanoparticles: 
The relationship between the particle size and solubility is described by the Ostwald-Freundlich 
equation, as follows15, 56: 
 
 
whereC (r) is the saturation solubility of particles of radius r, C* is thermodynamic  equilibrium 
solubility of particles,   γ is the interfacial tension between solid solute and solution,  M is the 
solute molecular weight, ρ is the density of the solute particle, and R is the gas constant. As 
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shown in equation 8, the saturation solubility of nanoparticles increases as the particle size, r, 
decreases. This is analogous to the well-known increase in vapor pressure over liquid droplets as 
the droplet size decreases. 
 
The aqueous solubility of CBZ nanocrystals in form III with different diameters is shown in table 
2. The thermodynamic saturation solubility of CBZ, 0.11mg/ml, was approximated as the 
aqueous solubility of as-received CBZ particles , whose average diameter is about 500±150 µm. 
The CBZ nanocrystals in form III were obtained by annealing electrosprayed CBZ nanoparticles 
at 90 ⁰C for 5 mins. From table 2, it is found that the solubility for CBZ nanocrystals with 
diameters of 960 nm, 540nm, and 320 nm increased over the bulk saturation solubility by 10.9%, 
17.3% and 26.4%, respectively. The interfacial tension between the nanocrystals and the solution 
was obtained to be 0.21 J/m2 with R2=0.99 by fitting the equation 8 to the solubility vs diameter 
data15.  
 
The dissolution rate of nanoparticles increases as the size of nanoparticles decreases mainly due 
to the increased surface to volume ratio as well as the higher solubility11. The representative 
dissolution curves of CBZ nanocrystals in form III were compared with that of CBZ particles as 
received. As shown in Figure 9, the dissolution rates for the electrosprayed nanocrystals are 
much higher than that of CBZ particles as received. The time for dissolving 50% CBZ materials, 
T50, is 3±3mins, 4±2mins, 8±3mins and 110±15 mins for CBZ nanocrystals with diameters of 
320 nm, 540 nm, 960 nm and CBZ particles as received, respectively. This indicates that for 
CBZ nanocrystals with a diameter of 320 nm, T50 is significantly reduced by approximately 
97.1% than that of as received CBZ particles.  
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Conclusions: 
An electrospray technique followed by annealing at high temperatures was developed to produce 
nanocrystals of CBZ, a poorly water-soluble drug, for continuous pharmaceutical manufacturing 
process. The effects of operating parameters and solution properties on morphology, crystallinity 
and polymorphism of CBZ nanocrystals produced by electrospray were characterized. Solutions 
of various concentrations of CBZ in methanol were electrosprayed to produce CBZ particles 
with diameters ranging from 320nm to several microns. During electrospraying, the CBZ 
solutions obey the scaling laws for spray current for liquids of sufficiently high viscosity and 
conductivity as expected. The diameter of the CBZ particles increased with flow rate. In order to 
produce dense nanoparticles with smaller, monodisperse diameter, lower flow rates were 
preferred to reduce or avoid the formation of a solid CBZ skin layer on the droplet surface, as 
well as to avoid Coulomb fission.  
 
The CBZ nanoparticles were predominately amorphous immediately after electrospraying, and 
crystallized gradually into a mixture of form III and form I during the storage time.  However, 
the crystallization process of CBZ nanoparticles could be accelerated by annealing at high 
temperatures. Form III, the most stable form at room temperature, was obtained by annealing at 
90 ⁰C for 5 mins, which is above the transition temperature, 78⁰C, for the enantiotropic CBZ 
form III and form I. For CBZ nanocrystals with a diameter of 320 nm, the solubility increased 
26.4 % and T50, the time to dissolve 50% of CBZ materials, decreased 97.1% compared to those 
of CBZ particles as received. Therefore, electrospray technology has the potential to produce 
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pharmaceutical dosage forms with enhanced bioavailability and can readily be integrated in a 
continuous pharmaceutical manufacturing process. 
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Figure 1, Nondimensionalized electrospray current versus nondimensionalized flow rate for all 
concentrations of CBZ solutions.  
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Figure 2, Comparison of measured diameters with calculated diameters of CBZ nanoparticles at 
various flow rates for different solutions (a) 0.5 wt% solution, (b) 1 wt% solution, (c) 3 wt % 
solution.   
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Figure 3, Representative SEM images of CBZ nanoparticles by electrospray at different 
concentrations and different flow rates  (a), Cw= 0.5 wt%, Q=0.003 ml/min; (b), Cw=0.5 wt%, 
Q=0.005 ml/min;(c) Cw: 0.5 wt%, Q= 0.01 ml/min;(d)Cw: 1 wt%, Q= 0.003 ml/min; (e)Cw: 3 
wt%, Q= 0.005 ml/min; (f)Cw: 5 wt%, Q= 0.02 ml/min. 
 
Figure 4: CBZ volume fraction at the Raleigh limit, ФRay ,vs flow rates,Q, at various CBZ 
concentrations. 
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Figure 5, X-ray diffraction spectrums of CBZ collected by a liquid nitrogen bath (a) CBZ 
nanoparticles by electrospray, (b) Bulk CBZ form III (c) Bulk CBZ form I. 
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Figure 6: X-ray diffraction spectrums of CBZ nanoparticles collected after 8 hours of continuous 
electrospray of 1 wt% CBZ solution,(a)  immediately after electrospray  (b) after 12 hours 
storage, (c) after 18 days of storage (d) CBZ bulk form I (e), CBZ bulk form III. 
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Figure 7: X-ray diffraction spectra of CBZ nanoparticles (a) annealed at 60 ⁰C for 5 mins, (b) 
annealed at 90 ⁰C for 5 mins, (c) annealed at 90 ⁰C for 40 mins. 
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Figure 8, DSC thermograms of CBZ nanoparticles (a) Immediately after 8 hours of continuous 
electrospray, (b) After the annealing at 90 ⁰C for 5 mins. (c) Bulk form III, (d) Bulk form I. 
 
Figure 9: The representative dissolution curves of CBZ nanocrystals and CBZ particles as 
received. 
 
 
 
 
